251 related articles for article (PubMed ID: 25107641)
1. MicroRNAs as regulatory elements in triple negative breast cancer.
Gyparaki MT; Basdra EK; Papavassiliou AG
Cancer Lett; 2014 Nov; 354(1):1-4. PubMed ID: 25107641
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs-mediated cell fate in triple negative breast cancers.
Sui X; Wang X; Han W; Li D; Xu Y; Lou F; Zhou J; Gu X; Zhu J; Zhang C; Pan H
Cancer Lett; 2015 May; 361(1):8-12. PubMed ID: 25748387
[TBL] [Abstract][Full Text] [Related]
3. Identification of dysregulated microRNAs in triple-negative breast cancer (review).
Yang F; Zhang W; Shen Y; Guan X
Int J Oncol; 2015 Mar; 46(3):927-32. PubMed ID: 25571912
[TBL] [Abstract][Full Text] [Related]
4. MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer.
Mathe A; Scott RJ; Avery-Kiejda KA
Int J Mol Sci; 2015 Nov; 16(12):28347-76. PubMed ID: 26633365
[TBL] [Abstract][Full Text] [Related]
5. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
[TBL] [Abstract][Full Text] [Related]
6. A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
García-Vazquez R; Ruiz-García E; Meneses García A; Astudillo-de la Vega H; Lara-Medina F; Alvarado-Miranda A; Maldonado-Martínez H; González-Barrios JA; Campos-Parra AD; Rodríguez Cuevas S; Marchat LA; López-Camarillo C
Tumour Biol; 2017 Jun; 39(6):1010428317702899. PubMed ID: 28621239
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer.
Zhang C; Han Y; Huang H; Min L; Qu L; Shou C
Int J Oncol; 2014 Jun; 44(6):2025-33. PubMed ID: 24676531
[TBL] [Abstract][Full Text] [Related]
8. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
11. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs in triple-negative breast cancer.
Koleckova M; Janikova M; Kolar Z
Neoplasma; 2018; 65(1):1-13. PubMed ID: 29322783
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer.
Tang Q; Ouyang H; He D; Yu C; Tang G
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2800-2809. PubMed ID: 31284781
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy of triple-negative breast cancer.
Arslan C; Dizdar O; Altundag K
Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
[TBL] [Abstract][Full Text] [Related]
15. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
16. High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer.
Cao ZG; Li JJ; Yao L; Huang YN; Liu YR; Hu X; Song CG; Shao ZM
Oncotarget; 2016 Oct; 7(40):64900-64909. PubMed ID: 27588500
[TBL] [Abstract][Full Text] [Related]
17. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
Schubert A; Hawighorst T; Emons G; Gründker C
Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
[TBL] [Abstract][Full Text] [Related]
18. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
19. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome.
Chu QD; Panu L; Holm NT; Li BD; Johnson LW; Zhang S
J Surg Res; 2010 Apr; 159(2):689-95. PubMed ID: 19500800
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]